Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
RMTI's Cash to Debt is ranked higher than
99% of the 702 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. RMTI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
RMTI' s 10-Year Cash to Debt Range
Min: 0.01  Med: 25.67 Max: No Debt
Current: No Debt
Equity to Asset 0.70
RMTI's Equity to Asset is ranked higher than
63% of the 563 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. RMTI: 0.70 )
Ranked among companies with meaningful Equity to Asset only.
RMTI' s 10-Year Equity to Asset Range
Min: -0.59  Med: 0.61 Max: 0.92
Current: 0.7
-0.59
0.92
F-Score: 6
Z-Score: 12.49
M-Score: -3.93
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -26.03
RMTI's Operating margin (%) is ranked lower than
85% of the 660 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.81 vs. RMTI: -26.03 )
Ranked among companies with meaningful Operating margin (%) only.
RMTI' s 10-Year Operating margin (%) Range
Min: -108.87  Med: -15.81 Max: 2.28
Current: -26.03
-108.87
2.28
Net-margin (%) -31.25
RMTI's Net-margin (%) is ranked lower than
86% of the 661 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.92 vs. RMTI: -31.25 )
Ranked among companies with meaningful Net-margin (%) only.
RMTI' s 10-Year Net-margin (%) Range
Min: -108.39  Med: -15.60 Max: 1.18
Current: -31.25
-108.39
1.18
ROE (%) -69.65
RMTI's ROE (%) is ranked lower than
91% of the 685 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.31 vs. RMTI: -69.65 )
Ranked among companies with meaningful ROE (%) only.
RMTI' s 10-Year ROE (%) Range
Min: -1304.41  Med: -33.13 Max: 6.43
Current: -69.65
-1304.41
6.43
ROA (%) -31.69
RMTI's ROA (%) is ranked lower than
88% of the 706 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.19 vs. RMTI: -31.69 )
Ranked among companies with meaningful ROA (%) only.
RMTI' s 10-Year ROA (%) Range
Min: -220.66  Med: -23.78 Max: 2.88
Current: -31.69
-220.66
2.88
ROC (Joel Greenblatt) (%) -802.27
RMTI's ROC (Joel Greenblatt) (%) is ranked lower than
91% of the 704 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.13 vs. RMTI: -802.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RMTI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2678.13  Med: -91.67 Max: 11.55
Current: -802.27
-2678.13
11.55
Revenue Growth (3Y)(%) -21.90
RMTI's Revenue Growth (3Y)(%) is ranked lower than
91% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. RMTI: -21.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
RMTI' s 10-Year Revenue Growth (3Y)(%) Range
Min: -23  Med: 1.70 Max: 36.8
Current: -21.9
-23
36.8
EBITDA Growth (3Y)(%) -30.10
RMTI's EBITDA Growth (3Y)(%) is ranked lower than
88% of the 483 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. RMTI: -30.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RMTI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -36.2  Med: -15.70 Max: 159.6
Current: -30.1
-36.2
159.6
EPS Growth (3Y)(%) -24.50
RMTI's EPS Growth (3Y)(%) is ranked lower than
79% of the 452 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.20 vs. RMTI: -24.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RMTI' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -18.30 Max: 109.9
Current: -24.5
0
109.9
» RMTI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

RMTI Guru Trades in

Q2 2013

RMTI Guru Trades in Q2 2013

Jim Simons 185,628 sh (New)
» More
Q3 2013

RMTI Guru Trades in Q3 2013

Jim Simons Sold Out
» More
Q1 2015

RMTI Guru Trades in Q1 2015

Paul Tudor Jones 25,170 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with RMTI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 136.99
RMTI's Forward P/E is ranked lower than
95% of the 232 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.27 vs. RMTI: 136.99 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 10.18
RMTI's P/B is ranked lower than
89% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.42 vs. RMTI: 10.18 )
Ranked among companies with meaningful P/B only.
RMTI' s 10-Year P/B Range
Min: 1.73  Med: 7.68 Max: 1425
Current: 10.18
1.73
1425
P/S 10.86
RMTI's P/S is ranked lower than
83% of the 653 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.30 vs. RMTI: 10.86 )
Ranked among companies with meaningful P/S only.
RMTI' s 10-Year P/S Range
Min: 0.47  Med: 2.10 Max: 14.18
Current: 10.86
0.47
14.18
PFCF 59.75
RMTI's PFCF is ranked lower than
63% of the 273 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 42.64 vs. RMTI: 59.75 )
Ranked among companies with meaningful PFCF only.
RMTI' s 10-Year PFCF Range
Min: 25.5  Med: 65.96 Max: 372.33
Current: 59.75
25.5
372.33
POCF 54.96
RMTI's POCF is ranked lower than
72% of the 385 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.53 vs. RMTI: 54.96 )
Ranked among companies with meaningful POCF only.
RMTI' s 10-Year POCF Range
Min: 19.62  Med: 42.04 Max: 186.17
Current: 54.96
19.62
186.17
EV-to-EBIT -43.62
RMTI's EV-to-EBIT is ranked lower than
180% of the 489 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.18 vs. RMTI: -43.62 )
Ranked among companies with meaningful EV-to-EBIT only.
RMTI' s 10-Year EV-to-EBIT Range
Min: -431.1  Med: -13.05 Max: 184.2
Current: -43.62
-431.1
184.2
Current Ratio 9.09
RMTI's Current Ratio is ranked higher than
88% of the 607 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.27 vs. RMTI: 9.09 )
Ranked among companies with meaningful Current Ratio only.
RMTI' s 10-Year Current Ratio Range
Min: 0.49  Med: 1.79 Max: 9.66
Current: 9.09
0.49
9.66
Quick Ratio 8.59
RMTI's Quick Ratio is ranked higher than
89% of the 606 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.66 vs. RMTI: 8.59 )
Ranked among companies with meaningful Quick Ratio only.
RMTI' s 10-Year Quick Ratio Range
Min: 0.35  Med: 1.44 Max: 9.26
Current: 8.59
0.35
9.26
Days Inventory 28.28
RMTI's Days Inventory is ranked higher than
91% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 113.56 vs. RMTI: 28.28 )
Ranked among companies with meaningful Days Inventory only.
RMTI' s 10-Year Days Inventory Range
Min: 18.25  Med: 24.35 Max: 46.23
Current: 28.28
18.25
46.23
Days Sales Outstanding 30.90
RMTI's Days Sales Outstanding is ranked higher than
83% of the 594 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.45 vs. RMTI: 30.90 )
Ranked among companies with meaningful Days Sales Outstanding only.
RMTI' s 10-Year Days Sales Outstanding Range
Min: 23.3  Med: 41.99 Max: 54.67
Current: 30.9
23.3
54.67

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.75
RMTI's Price/Net Cash is ranked lower than
51% of the 171 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.52 vs. RMTI: 12.75 )
Ranked among companies with meaningful Price/Net Cash only.
RMTI' s 10-Year Price/Net Cash Range
Min: 4.11  Med: 15.47 Max: 393.8
Current: 12.75
4.11
393.8
Price/Net Current Asset Value 10.57
RMTI's Price/Net Current Asset Value is ranked lower than
62% of the 361 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.04 vs. RMTI: 10.57 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
RMTI' s 10-Year Price/Net Current Asset Value Range
Min: 3.27  Med: 11.11 Max: 315
Current: 10.57
3.27
315
Price/Tangible Book 10.26
RMTI's Price/Tangible Book is ranked lower than
82% of the 614 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.15 vs. RMTI: 10.26 )
Ranked among companies with meaningful Price/Tangible Book only.
RMTI' s 10-Year Price/Tangible Book Range
Min: 2.66  Med: 8.23 Max: 95.01
Current: 10.26
2.66
95.01
Price/Median PS Value 5.13
RMTI's Price/Median PS Value is ranked lower than
97% of the 560 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. RMTI: 5.13 )
Ranked among companies with meaningful Price/Median PS Value only.
RMTI' s 10-Year Price/Median PS Value Range
Min: 0.2  Med: 0.93 Max: 4.27
Current: 5.13
0.2
4.27
Earnings Yield (Greenblatt) (%) -2.28
RMTI's Earnings Yield (Greenblatt) (%) is ranked lower than
78% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.30 vs. RMTI: -2.28 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RMTI' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -2.28  Med: 1.10 Max: 2.7
Current: -2.28
-2.28
2.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:RWM.Germany,
Rockwell Medical Inc was incorporated in the state of Michigan in 1996. The Company is a fully-integrated biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company manufactures, sells, delivers and distributes hemodialysis concentrates, along with a full line of ancillary products, to customers in the U.S. and abroad. Dialysate concentrates account for over 93% of its revenue and consist of two products known in the industry as acid and bicarbonate and are packaged as liquid or powder. All of its products are manufactured according to Association for the Advancement of Medical Instrumentation and current good manufacturing practices guidelines. Its concentrate products are used in conjunction and are diluted with clean water on-site at the clinic in the dialysis machine, creating dialysate, which works to clean the patient's blood. Its CitraPure concentrate is 100% acetate-free, in contrast to the acetate-based products used for many years. Acetate promotes inflammation so its removal is beneficial to the patient. Dry powder acid concentrate for use with its Dry Acid Mixing System, containing acetic acid, sodium chloride, dextrose and electrolyte additives such as magnesium, potassium, and calcium. It supplies dry acid in 25 gallon cases. Its Dry Acid Concentrate Mixing System is designed for its CitraPure and Dri-Sate Dry Acid product and allows a clinic to mix its acid concentrate on-site. The clinic technician, using a specially designed mixer, adds pre-measured packets of the necessary ingredients to purified water. RenalPure bicarbonate sold in powder form is used mainly in chronic settings. Each clinic mixes bicarbonate on-site as required. SteriLyte bicarbonate is sold in liquid form and is used in acute care settings. It offers ancillary products including blood tubing, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts and other supplies used by hemodialysis providers. Its largest competitor is U.S. based Fresenius Medical Care NA, which is mainly in the business of operating dialysis clinics, as well as manufacturing and marketing dialysis devices, drugs and supplies. The testing, manufacture and sale of its hemodialysis concentrates and the ancillary products it distribute are subject to regulation by numerous governmental authorities, mainly the FDA and corresponding state and foreign agencies.
» More Articles for RMTI

Headlines

Articles On GuruFocus.com
Brean Capital’s Top Ideas for 2015 Dec 24 2014 
Rockwell Medical Technologies Inc. (RMTI) Chairman, President and CEO, 10% Owner Robert L Chioini se Jan 03 2011 
Rockwell Medical Technologies Inc. (RMTI) Vice President, CFO Thomas E Klema sells 15,000 Shares Jan 03 2011 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) Nov 04 2010 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) Aug 05 2010 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) May 07 2010 
Rockwell Medical Technologies Inc. (RMTI) Chairman, President and CEO, 10% Owner Robert L Chioini se Jan 04 2010 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) Nov 06 2009 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) Aug 10 2009 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) May 11 2009 

More From Other Websites
Mesa Laboratories, Inc.: Leads amongst peers with strong fundamentals Aug 04 2015
Q2 2015 Rockwell Medical Inc Earnings Release - After Market Close Aug 04 2015
Rockwell Medical Schedules Second Quarter Earnings Call Jul 27 2015
Rockwell Medical Schedules Second Quarter Earnings Call Jul 27 2015
Mead Johnson Misses Q2 Earnings by a Penny; Guides Low - Analyst Blog Jul 23 2015
LifeSci Capital Initiates Coverage of Rockwell Medical, Inc. Jul 22 2015
Rockwell Medical Announces Triferic(TM) Phase 3 CRUISE Studies Published in Nephrology Dialysis... Jul 15 2015
Rockwell Medical Announces Triferic(TM) Phase 3 CRUISE Studies Published in Nephrology Dialysis... Jul 15 2015
Rockwell Medical Announces Triferic(TM) ESA-Sparing PRIME Study Published in Kidney International Jul 13 2015
Rockwell Medical Announces Triferic(TM) ESA-Sparing PRIME Study Published in Kidney International Jul 13 2015
Forget Baxter, Grab These 3 Medical Stocks Instead - Analyst Blog Jul 09 2015
Can the Rally in Rockwell Medical (RMTI) Shares Continue? - Tale of the Tape Jul 08 2015
These 3 Stocks Are Seeing Short-Selling Activity Rise Jul 07 2015
Can Rockwell Medical (RMTI) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape Jul 06 2015
Is Rockwell Medical Inc (RMTI) A Good Stock To Buy? Stock Spikes Over 8% Jun 25 2015
Rockwell Medical (RMTI) Worth Watching: Stock Up 11.3% - Tale of the Tape Jun 25 2015
Rockwell Medical Slumps: RMTI Falls 6.2% in Session - Tale of the Tape Jun 18 2015
Rockwell Medical, Inc. (RMTI) in Focus: Stock Jumps 5% - Tale of the Tape Jun 16 2015
Rockwell Medical Announces Triferic Receives Q-Code Assignment for Product Reimbursement Jun 01 2015
Rockwell Medical Announces Triferic Receives Q-Code Assignment for Product Reimbursement Jun 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK